[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hemiparesispoststrokecva\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hemiparesispoststrokecva":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,75,103,125,152,191],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":38,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":71,"locationsCount":74},"100612195","development-and-efficacy-of-a-novel-cost-effective-gait-training-device-utilized-at-home-for-stroke-survivors-100612195",false,"NCT07250425","Development and Efficacy of a Novel, Cost-Effective Gait Training Device Utilized at Home for Stroke Survivors","Development of a Novel, Cost-Effective Gait Training Device Utilized at Home for the Neurological Patient Population","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* First-ever ischemic or hemorrhagic stroke confirmed by medical record.\n* 3 months to 5 years post-stroke at time of enrollment.\n* Presence of lower-extremity motor impairment limiting walking function.\n* Able to stand for at least 30 minutes with no more than minimal assistance (with or without a device).\n* Medically stable and cleared by a physician to participate in moderate-intensity ambulation exercise.\n* Living in a home environment that can safely accommodate device installation (e.g., adequate space, appropriate flooring, and power access) as determined by the study team.\n* Able to understand study procedures and provide informed consent (or have a legally authorized representative), with sufficient cognitive and communication skills to follow simple instructions.\n* If assistance is required for transfers or device set-up, availability of a caregiver or assistant willing to participate in training and device use.\n\nExclusion Criteria:\n\n* Unstable cardiovascular, respiratory, or other medical conditions that contraindicate moderate- to high-intensity walking exercise (e.g., unstable angina, decompensated heart failure, uncontrolled arrhythmias).\n* Severe musculoskeletal or orthopedic conditions limiting safe participation in supported stepping (e.g., unstable fractures, severe contractures preventing positioning in the device).\n* Severe spasticity or movement disorders that would preclude safe use of the device, based on investigator judgment.\n* Severe cognitive impairment, aphasia, or behavioral disturbance that would prevent informed consent or safe participation.\n* Progressive neurological conditions (e.g., progressive neurodegenerative disease) expected to significantly worsen over the 12-week study period.\n* Current participation in another interventional trial targeting gait or lower-extremity function.\n* Any other condition that, in the opinion of the investigators, would make participation unsafe or interfere with study adherence or outcome interpretation.","ALL","18 Years","75 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"NA","This pilot, parallel-group randomized controlled trial will evaluate the feasibility, safety, usability, and preliminary efficacy of the Rise\\&Walk InHome (RWH), a novel robotic gait training device designed for home use after stroke. Twenty adults with lower-extremity motor impairment following a first-ever stroke (3 months to 5 years post-event) will be randomized 1:1 to either (1) RWH-assisted home walking plus usual care or (2) usual care alone for 12 weeks. Participants in the intervention group will receive an in-home RWH device, complete a structured device training program, and be instructed to perform 30-minute RWH walking sessions four times per week (48 sessions total). All participants will undergo standardized outcome assessments at baseline, weeks 4, 8, and 12, including the 6-Minute Walk Test (primary outcome), 10-Meter Walk Test, daily step count via wearable activity tracker, and health-related quality of life (SF-36). Additional feasibility and usability outcomes include device use and adherence, patient satisfaction and motivation, ease of use, perceived exertion, and adverse events. Findings will inform the feasibility of in-home deployment of the RWH device and provide preliminary effect-size estimates to guide the design of a larger efficacy trial.",[27,28,29,30,31,32,33,34,35,36,37],"Stroke","Neurological Diseases or Conditions","Hemiparesis;Poststroke\u002FCVA","Gait Disorders, Neurologic","Post Stroke Fatigue","Motor Recovery","Walking Difficulty","Balance Impairment","Falls Prevention","Hemiparesis","Mobility Limitation",[39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62],"in-home rehabilitation","Robotic-Assisted Gait Training","gait training device","stroke recovery","functional mobility","rehabilitation technology","remote monitoring","rehabilitation robotics","Fitbit Step Tracking","Self-Directed Gait Training","high-intensity gait training","Neurorehabilitation Research","Lower Limb Rehabilitation","Motor Function Recovery","Physical Therapy","Walking Endurance","task specific walking practice","neurological recovery","stroke rehabilitation","home exercise program","Rise&Walk InHome","daily step count","6-minute walk test","10-meter walk test","NOT_YET_RECRUITING","2026-03-06",{"date":66,"type":67},"2026-03-09","ACTUAL",{"date":69,"type":21},"2026-08",{"date":69,"type":21},{"name":72,"class":73},"Healing Innovations","OTHER",1,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":74},"100577350","a-novel-wrist-wearable-sensor-system-to-promote-hemiparetic-upper-extremity-use-in-subacute-stroke-survivors-100577350","NCT06797154","A Novel Wrist Wearable Sensor System to Promote Hemiparetic Upper Extremity Use in Subacute Stroke Survivors","A Novel Wrist Wearable Sensor System to Promote Hemiparetic Upper Extremity Use in Home Daily Life of Subacute Stroke Survivors","Inclusion Criteria:\n\n* Male or female, 18-85 years of age at the time of enrollment\n* Anterior circulation ischemic stroke at least 1 month and no more than 6 months prior to study enrollment;\n* Unilateral upper extremity hemiparesis as characterized by initial scores on upper limb subtest of the Fugl-Meyer Assessment (FMA-UE) between 20 and 45;\n* Intact cognitive function to understand the study procedures and goal setting (MMSE score above 23 and able to follow 3step command) ;\n* Owning a smartphone (iOS or Android) and being familiar and comfortable with and owning a tablet or smartphone\n* SAFE score equal or greater than 5\n\nExclusion Criteria:\n\n* Severe spasticity (defined as a Modified Ashworth scale score of 3 or more) that would prevent safe performance of UE tasks;\n* Visual impairments as assessed by the NIH Stroke Scale Visual Field subscale (only subjects with no visual loss will participate in the study); or hemispatial neglect that would impair the subject ability to see the feedback on the app screen (as assessed with the Mesulum cancellation test);\n* Individuals with open wounds or recent fracture (less than 3 months) in the upper extremity, fragile skin or active infection;\n* Upper-extremity orthopedic injuries or severe pain resulting in movement limitations;\n* Diagnosis of other neurological disease; (i.e., Parkinson's disease, multiple sclerosis, ...);\n* Severe proprioceptive deficits that impair the ability to process the vibration feedback, as assessed by physical examination during screening;\n* Not understanding spoken or written English;\n* Contralateral motor deficits as assessed by clinical examination;\n* Brainstem and cerebellar stroke.","85 Years",{"count":84,"type":21},88,[24],"The proposed study is a two-arm randomized clinical trial designed to assess the effects of the StrokeWear system on clinical outcomes over a period of 6-months in subacute stroke survivors. The Intervention group will use StrokeWear system in combination to a motor and behavioral home intervention whereas the Control group will follow usual care which consists of a home-exercise plan (HEP).",[27,88,29],"Stroke Sequelae",[90,91,92],"StrokeWear","Biosensics","Behavioral Intervention","RECRUITING","2025-11-21",{"date":96,"type":67},"2025-11-28",{"date":98,"type":67},"2025-08-08",{"date":100,"type":21},"2026-08-31",{"name":102,"class":73},"Spaulding Rehabilitation Hospital",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":82,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":112,"briefSummary":114,"conditions":115,"keywords":116,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":119,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":74},"100487423","phase-2-novel-wrist-sensor-system-to-promote-hemiparetic-arm-use-in-home-daily-life-of-chronic-stroke-survivors-100487423","NCT05626894","Novel Wrist Sensor System to Promote Hemiparetic Arm Use in Home Daily Life of Chronic Stroke Survivors","A Novel Wrist Wearable Sensor System to Promote Hemiparetic Upper Extremity Use in Home Daily Life of Chronic Stroke Survivors","Inclusion Criteria:\n\n* Male or female, 18-85 years of age at the time of enrollment;\n* Anterior circulation ischemic stroke at least 6 months and up to 5 years prior to study enrollment;\n* Unilateral upper extremity hemiparesis as characterized by initial scores on upper limb subtest of the Fugl-Meyer Assessment (FMA-UE) between 20 and 45;\n* Intact cognitive function to understand the study procedures and goal setting (MMSE score above 23 and able to follow 3 step command);\n* Being familiar and comfortable with the use of a tablet or smartphone.\n\nExclusion Criteria:\n\n* Severe spasticity (defined as a Modified Ashworth scale score of 3 or more) that would prevent safe performance of UE tasks;\n* Visual impairments as assessed by the NIH Stroke Scale Visual Field subscale (only subjects with no visual loss will participate in the study); or hemispatial neglect that would impair the subject ability to see feedback on the app screen (as assessed with the star cancellation test);\n* Individuals with open wounds or recent fracture (less than 3 months) in the UE, fragile skin or active infection as evaluated by the study therapist;\n* Individuals currently enrolled in a UE rehabilitation program (i.e., OT, research study)\n* Upper-extremity orthopedic injuries or severe pain resulting in movement limitations;\n* Diagnosis of other neurological disease (i.e., Parkinson's disease, multiple sclerosis, ...);\n* Severe proprioceptive deficits that impair the ability to process the vibration feedback, as assessed by physical examination during screening as assessed by the study therapist;\n* Not understanding spoken or written English;\n* Recent (less than 3 months) Botox injection in the UE or plan to undergo injections during the study timeline;\n* Contralateral motor deficits as assessed by clinical examination;\n* Brainstem and cerebellar stroke.",{"count":111,"type":21},32,[113],"PHASE2","The proposed study is a two-arm randomized clinical trial designed to assess the effects of the StrokeWear system on clinical outcomes over a period of 6-months in chronic stroke survivors. The Intervention group will use StrokeWear system in combination to a motor and behavioral home intervention whereas the Control group will follow usual care which consists of a home-exercise plan (HEP).",[27,88,29],[90,117,118],"BioSensics","Behavioral intervention",{"date":96,"type":67},{"date":121,"type":67},"2025-03-20",{"date":123,"type":21},"2026-09-30",{"name":102,"class":73},{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":133,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":22,"phases":136,"briefSummary":137,"conditions":138,"keywords":139,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":74},"100533821","effects-of-functional-electrical-stimulation-assisted-cycling-in-patients-with-hemiparesis-after-stroke-100533821","NCT06230796","Effects of Functional Electrical Stimulation Assisted Cycling in Patients With Hemiparesis After Stroke","Effects of FES-cycling in Patients With Hemiparesis After Stroke","AVCyclES","Inclusion Criteria:\n\n* Adults with Hemiparesis after an unilateral first ever stroke\n* Able to walk in security\n* Time since stroke within 3 months to 1 year\n* Sufficient cognitive function to understand and perform corresponding tasks\n\nExclusion Criteria:\n\n* Any history of neurological disorders or cardiovascular instability\n* High spasticity on ankle, knee, hip muscles\n* Inability to exercise on a cyclo-ergometer\n* Pacemaker and other contraindications of the use of electrical stimulation",true,{"count":135,"type":21},30,[24],"To determine whether active cycling assisted by functional electrical stimulation (FES) Is more effective than active cycling on cardiovascular fitness in post stroke hemiparesis",[29],[140,141,142],"cycling","exercises","functional electrical stimulation","2025-09-17",{"date":145,"type":67},"2025-09-19",{"date":147,"type":67},"2023-11-17",{"date":149,"type":21},"2025-12-01",{"name":151,"class":73},"UGECAM Rhône-Alpes",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":22,"phases":161,"briefSummary":162,"conditions":163,"keywords":171,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":190},"100524306","effects-of-atalante-exoskeleton-on-gait-recovery-in-non--or-poorly-ambulatory-patients-with-hemiparesis-in-the-acutesubacute-phase-month-1-to-4-100524306","NCT06107010","Effects of Atalante Exoskeleton on Gait Recovery in Non- or Poorly Ambulatory Patients With Hemiparesis in the Acute\u002FSubacute Phase (Month 1 to 4)","EarlyExo","Inclusion Criteria:\n\n* \\>18 years old\n* First clinically significant disability due to stroke\n* Hemiparesis in acute-subacute phase (1 to 4 months since lesion) due to a stroke\n* Functional Ambulation Category score (FAC) \\\u003C2\n* Patient with health insurance\n* Informed and willing to sign an informed consent form approved by the Ethics Committee. For clarity, if a motor impairment prevents the subject from signing by himself, he\u002Fshe can still be included if the signature can be done by an impartial witness.\n\nExclusion Criteria:\n\n* Muscle overactivity in hip adductors, hamstrings, quadriceps and plantar flexors, which interferes with exoskeleton use, based on clinician investigator's opinion\n* Recent fracture (\\\u003C 3 months) or any therapy inducing secondary osteoporosis\n* Excessive joint mechanical pain in the lower limbs based on clinician investigator's opinion\n* Pressure sore grade I or more over contact zones with Atalante system, according to the International Pressure Ulcer Classification System NPUAP - EPUA\n* Medical contra-indication to medium intensity physical strain\n* Orthostatic hypotension (loss of \\> 20 mmHg systolic BP after 3 minutes in standing position)\n* Uncontrolled seizures\n* Morphological contra-indications to the use of Atalante (as per user's manual)\n* Pregnant woman\n* Adults who lack the capacity to provide informed consent, and all those persons deprived of their liberty in prisons or other places of detention\n* Concurrent participation in another interventional trial",{"count":160,"type":21},66,[24],"The present clinical investigation - EarlyExo, is an interventional, international, multicentric, prospective, single-blinded randomized controlled trial.\n\nThis clinical investigation is designed to test the hypothesis that early and intense introduction of walking sessions assisted by the Atalante exoskeleton, in a sample of hemiparetic patients with still non or poor ambulatory capacities (FAC 0 or 1) between one- and four-months post stroke, would result in a better recovery of functional walking compared to a control group only receiving conventional therapy. Improved recovery will be measured through the proportion of patients reaching a FAC score of 4 or higher at the end of the intervention period. The tested hypothesis is that this proportion will be higher in the Exo group.\n\nThe duration of the intervention period in both groups is 6 weeks.\n\n* For the Exo group: 3 sessions per week (i.e., 18 one-hour sessions) with the Atalante device and 2 sessions per week (i.e., 12 one-hour sessions) of conventional therapy.\n* For the Control group: 5 sessions per week of conventional therapy (i.e., 30 one-hour sessions).\n\nThe study will include 66 patients (33 in each arm) and takes place in two French centers, two German centers and one Spanish center.",[164,165,166,167,168,169,36,29,170],"Stroke, Acute","Stroke, Ischemic","Stroke, Subacute","Stroke Hemorrhagic","Cerebrovascular Disorders","Cerebrovascular Accident","Hemiparesis\u002FHemiplegia (One Sided Weakness\u002FParalysis)",[172,173,174,175,27,176,177,178,179],"Robotics","Rehabilitation","Powered Exoskeleton","Walking recovery","Acute stroke","Subacute stroke","Functional Ambulation Category","Randomized controlled study","2025-01-30",{"date":182,"type":67},"2025-02-04",{"date":184,"type":67},"2023-06-12",{"date":186,"type":21},"2026-02-28",{"name":188,"class":189},"Wandercraft","INDUSTRY",5,{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":197,"eligibilityCriteria":198,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":199,"enrollmentInfo":200,"targetDuration":4,"studyType":22,"phases":201,"briefSummary":202,"conditions":203,"keywords":207,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":219},"100560284","associative-peripheral-stimulation-for-reduction-of-motor-impairment-during-acute-period-of-stroke-recovery-100560284","NCT06575140","Associative Peripheral Stimulation for Reduction of Motor Impairment During Acute Period of Stroke Recovery","Pilot Randomized Controlled Trial Assessing Associative Peripheral Stimulation (APS) for Reduction of Motor Impairment During Acute Period of Stroke Recovery","APS-PILOT","Inclusion Criteria:\n\n1. Confirmed ischemic or hemorrhagic stroke no earlier than 7 days prior to enrollment;\n2. Presentation of hemiparesis or paralysis of the upper extremity due to stroke;\n3. Ability to comprehend and follow study instructions;\n4. Ability to initiate finger extension (≥3°) at least three times per minute;\n5. Fugl-Meyer Assessment (Upper Extremity) score of \\\u003C47.\n\nExclusion Criteria:\n\n1. Contraindications, intolerance, or high sensitivity to the experimental protocol;\n2. History of upper-extremity disability prior to the index stroke;\n3. Neurological conditions (other than stroke) affecting motor function;\n4. Treatment of spasticity\u002Fincreased tone in the affected upper extremity (e.g., with Botox injection);\n5. Lack of access to a safe and suitable place of discharge for experimental sessions and follow-up visits.","79 Years",{"count":20,"type":21},[24],"Associative Peripheral Stimulation (APS) is a non-invasive therapy intended for stroke rehabilitation involving transcutaneous electrical muscle stimulation paired with voluntary movement. This pilot study investigates whether APS applied during the acute phase of stroke recovery may reduce impairment and improve function in the affected upper extremity.",[27,164,165,204,36,29,205,88,206],"Stroke, Hemorrhagic","Weakness of Extremities as Sequela of Stroke","Upper Extremity Paresis",[208,209],"Stroke Rehabilitation","Associative Peripheral Stimulation","2024-08-28",{"date":212,"type":67},"2024-08-30",{"date":214,"type":67},"2021-12-18",{"date":216,"type":21},"2024-12",{"name":218,"class":73},"Ahmed A. Rahim",3]